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Drug disposition is critically dependent upon the physico-
chemical characteristics of the drug itself, together with a number
of physiological factors. In neonates, infants and children, those
physiological factors which influence drug disposition (renal and
hepatic function, metabolic rate) change rapidly during maturation
(Crom et al, 1987, 1991; McLeod et al, 1992). These are accompa-
nied by significant age-related changes in body composition
(extracellular and total body water, fat distribution, lean body
mass) (Friss-Hansen, 1961). The combined effect of these changes
on the pharmacokinetic parameters of any drug may significantly
influence systemic drug exposure. Drug clearance, and by defini-
tion systemic exposure, also shows wide inter- and intra-patient
variation (Crom et al, 1987). This wide variation in systemic expo-
sure may have a significant effect on disease response (Evans et al,
1998) and drug toxicity. Since changes in these physiological and
pharmacokinetic parameters were thought to correlate most
closely with Body Surface Area (BSA), it is this measurement
which forms the basis of dose normalization with respect to varia-
tions in age, body size and body composition. This convention for
drug dosing has recently been questioned (Gurney, 1996; Ratain,
1998), but aside from regimens incorporating pharmacokinetically
guided treatment (Galpin and Evans, 1993; Desoize and Robert,
1994; Boos et al, 1995) and adaptive control of free-drug expo-
sure, dosing of chemotherapeutic agents based on patient BSA is
still the method employed in the majority of current paediatric
treatment protocols. 
There are a large number of publications describing formulae
and/or nomograms to estimate BSA from patient height and
weight (DuBois and DuBois, 1916; Boyd, 1935; Sendroy and
Cechini, 1952; Haycock and Schwarz, 1978; George and Gehan,
1979; Mosteller, 1987). Many of these formulae are derived by
painstaking direct measurement of BSA using a variety of tech-
niques, but often in a small number of subjects. The perceived
advantages of any one of these methods in determining BSA in
children, either in terms of accuracy or ease of use, are question-
able and serious errors in the use of these techniques have also
been described (Briars and Bailey, 1994). Similarly, sliding-scale
BSA nomograms and BSA calculators produced by drug compa-
nies, and frequently used as ‘aids to prescribing’, are based almost
universally on the formula described by Dubois (DuBois and
DuBois, 1916). This formula was derived from a small subject
sample (n = 9), which included only one child and has been shown
to significantly underestimate BSA in children less than 0.7 m2
(Haycock and Schwarz, 1978). 
Perhaps most importantly however, all of these methods require
an accurate measurement of patient height and weight.
Paediatricians and paediatric nurses will be familiar with the prob-
lems in obtaining accurate, reproducible measurement of patient
height or supine length in children. 
A method describing estimation of BSA from body weight
(BW) alone has been described by Coulthard (Coulthard, 1994)
and was based on one of the largest single bodies of work under-
taken in direct surface-area measurement (Boyd, 1935). In the
latter study, Boyd proposed that the application of a self-adjusting
power equation (SAPE) in which weight is raised to a power
which varies with its own value is so accurate in determining 
BSA that the ‘advantage of using a similar equation requiring 
a height determinant was reduced to insignificance’ (Coulthard,
1994). 
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doi: 10.1054/ bjoc.2001.1859, available online at http://www.idealibrary.com on  http://www.bjcancer.comThe application of the formula of Boyd to dosing in paediatric
oncology regimens has been investigated in the current study. This
evaluation led to the development of a simple table for use in
paediatric oncology clinics for the dosing of drugs to children with
cancer. 
METHODS 
The analysis of Boyd was used to calculate BSA for patients over
the range of weights typically seen in paediatric oncology (2–
90 kg). Equation 1 gives the relationship between BSA (in cm2)
and weight (W) in g, as described by Boyd. This was corrected
for the units of m2 and kg in performing the analysis. 
BSA = 4.688 l W (0.8168–0.0154 
l logW) (1)
Particular attention was paid to those patients weighing less than
10 kg (Table 1). Patients greater than 10 kg were examined
separately (Table 2). 
Since prescribers currently use a variety of methods to estimate
BSA in their patients, this study has compared results obtained in a
cohort of paediatric patients using the values in Tables 1 and 2 and
two of the most commonly used alternative methods requiring a
height and weight measurement: 
(a) Mosteller formula: 
where BSA is in m2, H (height) is in cm and W (weight) in kg. 
(b) Sliding scale nomogram (pharmaceutical company
prescribing aid), based on the DuBois formula: 
A = W0.425 ´ H0.725 ´ 71.84 (3)
A = surface area in cm2, H is height in cm and W is weight in kg. 
Measurements of height and weight were carried out in the
normal way for a cohort of patients (n = 146) of both sexes, treated
at 2 UKCCSG centres (100 from RVI, Newcastle and 46 from
Birmingham Children’s Hospital). The range of weights was 11.0
to 86.6 kg, with a median weight of 42.8 kg. None of the patients
were clinically obese or cachectic. Children less than 10 kg were
excluded as a reliable measure of height is not possible in these
patients. BSA was estimated from Table 2 (Boyd formula) and
compared with results obtained from the Mosteller formula and
the DuBois nomogram. For each comparison, the percentage devi-
ation of the Boyd formula from the conventional method was
calculated. To determine if patients of differing sizes were more
prone to bias or imprecision in BSA calculation, data were
grouped into 3 weight categories: 10–30 kg, 31–50 kg and greater
than 50 kg. 
RESULTS 
When calculated using the Boyd formula (1), over the range of
body weights considered for paediatric oncology patients, BSA
varies from 0.16 to 0.49 m2 for patients less than 10 kg (Table 1)
and increases from 0.53 to 2.2 m2 for patients weighing from 11 to
90 kg (Table 2). For all the data, the variations in BSA estimation
between the Mosteller formula, the Dubois nomogram and the
table based on the Boyd equation are displayed in Figures 1 and 2.
The percentage variation of the Boyd formula from the estimates
obtained by the algorithms requiring height is less than 15% in
every case, and less than 10% in all but 2 patients in comparison
with Mosteller, and 6 patients in comparison with Dubois. The
proportions of patients within 5% of the estimate of BSA provided
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BSA =    H ´ W
                3600
(2)
Table 1 BSA estimation in patients less than 10 kg. Values are calculated
using the Boyd formula (1) 
Body weight (kg) Surface area (m2) 
2 0.16 
2.5 0.19 
3 0.21 
3.5 0.24 
4 0.26 
4.5 0.28 
5 0.3 
5.5 0.32 
6 0.34 
6.5 0.36 
7 0.38 
7.5 0.4 
8 0.42 
8.5 0.44 
9 0.46 
9.5 0.47 
10 0.49 
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Figure 1 Plot of the percentage deviation of the calculated surface area
using the Boyd formula (1) based on weight alone, when compared to the
Mosteller formula (2) 
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Figure 2 Plot of the percentage deviation of the calculated surface area
using the Boyd formula (1) based on weight alone, when compared to the
Dubois formula (3) by the more conventional methods were 84% and 73% respec-
tively. There was no effect of gender on the concurrence of the
different calculation methods. 
Categorization of the subjects according to weight did not reveal
any trends to under- or overestimation of BSA using the Boyd
equation compared to Mosteller or Dubois. Mean prediction error
(MPE), or bias, was 1.1, –1.8 and 2.1% for patients less than
30 kg, 30–50 kg and greater than 50 kg respectively (comparing
Boyd with Dubois). Corresponding values for mean absolute
prediction error (MAPE), or precision, were 3.3, 3.8 and 4.2%.
Comparison of Boyd with Mosteller produced values for MPE and
MAPE indicating less bias and higher precision in each of the
weight categories. 
Reliable data were available only from patients weighing over
10 kg. To assess the impact of implementing the Boyd formula in
smaller patients, calculations were made of the dosing implica-
tions for a typical child on a paediatric drug treatment protocol
(Table 3). In this protocol, drugs are administered at doses based
on BSA for patients greater than 10 kg, and based on weight for
smaller children. Dosing based on surface area would result in an
increase in dose for children less than 10 kg of between 65 and
92%, compared to current practise, in this protocol. 
DISCUSSION 
Dosing based on BSA is founded largely in the history of cytotoxic
drug development (Ratain, 1998) and despite its many limitations
remains the method employed in the majority of current treatment
protocols. With the majority of cytotoxic agents, drug clearance
and by definition systemic exposure correlates only loosely with
either body weight or BSA. In particular, there is little sound phys-
iological, pharmacokinetic or pharmacodynamic data to support
BSA-based dosing of many cytotoxic drugs. In some cases, closer
correlations exist between some other measurable parameter e.g.
carboplatin clearance and glomerular filtration rate (GFR) and this
has formed the basis for GFR-based dosing regimes in many
paediatric and adult treatment protocols (Calvert et al, 1989;
Newell et al, 1993). These variations in inter-individual drug
handling have stimulated recent research into the individualization
of treatment of paediatric cancers in order to optimize outcome
Body surface area estimation using weight alone 25
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Table 2 BSA estimation in patients greater than 10 kg. Values are calculated using the Boyd formula (1) 
Body weight (kg) Surface area (m2) 
11 0.53 
12 0.56 
13 0.59 
14 0.62 
15 0.65 
16 0.68 
17 0.71 
18 0.74 
19 0.77 
20 0.79 
21 0.82 
22 0.85 
23 0.87 
24 0.9 
25 0.92 
26 0.95 
27 0.97 
28 1.0 
29 1.0 
30 1.1 
31 1.1 
32 1.1 
33 1.1 
34 1.1 
35 1.2 
36 1.2 
37 1.2 
38 1.2 
39 1.3 
40 1.3 
41 1.3 
42 1.3 
43 1.3 
44 1.4 
45 1.4 
46 1.4 
47 1.4 
48 1.4 
49 1.5 
50 1.5 
Body weight (kg) Surface area (m2) 
51 1.5 
52 1.5 
53 1.5 
54 1.6 
55 1.6 
56 1.6 
57 1.6 
58 1.6 
59 1.7 
60 1.7 
61 1.7 
62 1.7 
63 1.7 
64 1.7 
65 1.8 
66 1.8 
67 1.8 
68 1.8 
69 1.8 
70 1.9 
71 1.9 
72 1.9 
73 1.9 
74 1.9 
75 1.9 
76 2.0 
77 2.0 
78 2.0 
79 2.0 
80 2.0 
81 2.0 
82 2.1 
83 2.1 
84 2.1 
85 2.1 
86 2.1 
87 2.1 
88 2.2 
89 2.2 
90 2.2 and reduce drug toxicity (Evans et al, 1998). However, with the
exceptions of carboplatin, methotrexate and 6-mercaptopurine, no
rational approach to individualized dosing of drugs administered
to paediatric patients has emerged, and surface area is the most
commonly used parameter with which to adjust doses for the wide
range of body sizes encountered in paediatric oncology. 
Many methods have been employed and formulae derived to esti-
mate BSA. These methods should not be accepted as a precise
measurement of BSA, but rather as techniques which will allow
comparison between individuals (Pinkel, 1958). Against this back-
ground, we have identified and validated a method which standard-
izes BSA measurement in children and reduces the possible errors
attendant in the use of nomograms and formulae. Given the difficul-
ties in measuring height in children and the implications that this
may have on the accuracy of any calculation, the table derived from
the Boyd formula estimates BSA values without significant variation
from either of the 2 methods tested in this study. These comparisons
are not absolute, as there is no definitive estimate of BSA offered by
any of the proposed methods. However, the method proposed here is
simpler and easier to apply in a more consistent manner. This should
reduce errors in dose calculation and provide more uniformity of
doses administered, thus removing possible confounding effects in
the interpretation of multicentre clinical trials. 
This method has been validated in children greater than 10 kg, and
can be recommended for application to drug protocols for this group
of patients. However, the majority of paediatric protocols apply a cut-
off for surface area based dosing at 10 kg. Below this weight, the
dosing of chemotherapeutic drugs is specified on a mg kg-1 basis,
usually based on an approximate extrapolation from a 1 m2individual
assumed to weight 30 kg, and assuming a linear relationship between
weight and BSA. However, in children less than 10 kg body weight,
this results in a significant reduction in dose compared to the refer-
ence dose for a larger child calculated on the basis of BSA (Table 3). 
This cautious approach to drug dosing in infants and younger
children is designed to avoid excessive myelosuppression and
other significant drug toxicities resulting from impaired drug 
elimination (reduced biliary excretion, decreased renal-tubular
excretion, hepatic enzyme immaturity) in very young infants
(< 6 kg) (Woods et al, 1981; Reaman, 1993). 
However, the assumption of reduced hepatic and renal function
has not been borne out by recent investigations (Newell et al,
1993; Blanco et al, 2000) and these adjustments are applied across
a significant weight range. There is a likelihood that sub-
therapeutic dosing occurs in some patients within this group. Also
there is the problem of the significant step-up in dosage as children
cross the 10 kg boundary, and move from mg kg–1 to mg m–2 dosing
during their treatment. Both of these issues have implications in
terms of both disease response and drug toxicity. 
In the context of the clinical application of the Boyd formula,
the UKCCSG has recommended that the BSA table be used to
estimate body surface area in infants under 10 kg in weight in
order to provide a smoother transition in dosing for this group of
patients. It is recommended that the question of dose reduction in
infants less than 12 months of age should be addressed by indi-
vidual investigators and protocols. In order to assist protocol
designers in the selection of appropriate starting doses of
chemotherapeutic agents in children less than 12 months of age or
less than 10 kg body-weight, guidelines have been produced by
the UKCCSG and are attached as an appendix. 
There are limits to the application of any algorithmic method in
the calculation of drug dosages (Gurney, 1996; Smith, 1996). In
severely malnourished or obese patients BSA estimation based on
any algorithm with a weight parameter may result in inappropriate
dosing. The tables proposed here for the estimation of BSA, and
thus cytotoxic drug doses, must be taken in conjunction with a
clinical assessment of the patient, including the implications of co-
existing illness, previous chemo- or radiotherapy, concurrent drug
treatment and nutritional status. 
Concern has been expressed in a number of publications and
editorials that paediatric patients may be receiving inappropriate
doses because of inadequate methods for the estimation of BSA,
and lack of standardization of methods between study centres. To
address this concern, and to provide standardized dosing of
chemotherapeutic agents in UKCCSG trials, the Boyd estimates of
BSA, based on body weight alone, have been used to construct a
table from which the BSA can be calculated. The table is simple
and uncomplicated to use, and overcomes the significant errors in
determining height measurements in children and infants. 
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Table 3 Comparison of chemotherapy dosing using body weight v body surface area 
Drug Dose by weight Dose by SA Ratio of doses 
Vincristine 
1.5 mg m–2 0.25 mg 0.45 mg 1.80 
0.05 mg kg–1
Carboplatin 
550 mg m–2 100 mg 165 mg 1.65 
20 mg kg–1
Methotrexate 
8g  m –2 1.25 g 2.4 g 1.92 
250 mg kg–1
Cisplatin 
40 mg m–2 6.5 mg 12 mg 1.85 
1.3 mg kg–1
Example: Protocol UKCCSG Skudy CNS 9204 (Baby Brain). Patient wt = 5 kg. 
Estimated BSA = 0.3 m2 (from Table 1) using the Boyd formula. REFERENCES 
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Appendix Guidelines for dose adjustments in children less than 10 kg or less than 12 months of age 
Caution
l For children less than 10 kg body-weight, dosing by body surface area represents a change in usual clinical practice: This will
result in an increase in calculated dose. 
l The implications of this change, in clinical practice, are not known in terms of drug toxicity. 
l Recommendations: 
Starting doses: For infants less than 6 months of age: 
50% of calculated dose by body surface area. 
For infants 6 months to 1 year of age: 
75% of calculated dose by body surface area. 
For infants over 1 year of age: 
100% of calculated dose by body surface area. 
l These doses may be adjusted according to clinical circumstances. 
l Individual investigators (and protocols) should have clear recommendations for dosing in infants, and should monitor both
disease response and toxicity closely in order to identify any clinical problems related to change in chemotherapy doses. 